Adjusted HRs from multivariate analysis of OS
| Characteristic . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Study | |||
| Immunosuppression (GTH-AH 01/2010) | 1 | — | |
| Emicizumab (GTH-AHA-EMI) | 0.37 | 0.16-0.85 | .019∗ |
| Age, y | |||
| >74 | 1 | — | |
| ≤74 | 0.50 | 0.25-1.01 | .052 |
| Sex | |||
| Female | 1 | — | |
| Male | 1.38 | 0.67-2.81 | .382 |
| FVIII activity, IU/dL | |||
| <1 | 1 | — | |
| ≥1 | 0.51 | 0.24-1.09 | .082 |
| Inhibitor, BU/mL | |||
| >20 | 1 | — | |
| ≤20 | 0.93 | 0.39-2.20 | .866 |
| WHO-PS | |||
| Poor (>2) | 1 | — | |
| Good (≤2) | 0.51 | 0.23-1.13 | .097 |
| Malignancy | 2.17 | 0.77-6.08 | .142 |
| Renal disease | 1.80 | 0.80-4.05 | .158 |
| Diabetes mellitus | 0.81 | 0.36-1.79 | .596 |
| Characteristic . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Study | |||
| Immunosuppression (GTH-AH 01/2010) | 1 | — | |
| Emicizumab (GTH-AHA-EMI) | 0.37 | 0.16-0.85 | .019∗ |
| Age, y | |||
| >74 | 1 | — | |
| ≤74 | 0.50 | 0.25-1.01 | .052 |
| Sex | |||
| Female | 1 | — | |
| Male | 1.38 | 0.67-2.81 | .382 |
| FVIII activity, IU/dL | |||
| <1 | 1 | — | |
| ≥1 | 0.51 | 0.24-1.09 | .082 |
| Inhibitor, BU/mL | |||
| >20 | 1 | — | |
| ≤20 | 0.93 | 0.39-2.20 | .866 |
| WHO-PS | |||
| Poor (>2) | 1 | — | |
| Good (≤2) | 0.51 | 0.23-1.13 | .097 |
| Malignancy | 2.17 | 0.77-6.08 | .142 |
| Renal disease | 1.80 | 0.80-4.05 | .158 |
| Diabetes mellitus | 0.81 | 0.36-1.79 | .596 |
P < .05 (Wald test).